Active Investments

Aclaris Therapeutics
Specialty pharmaceutical dermatology company focused on the development of novel dermatologic therapies.
Aerie Pharmaceuticals
Clinical-stage biotechnology company dedicated to the discovery and development of novel treatments for glaucoma.(NASDAQ:AERI)
Alimera Sciences
Specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals.(NASDAQ:ALIM)
Alvine
Developing biologics to target celiac disease. Partnered with Abbvie.
Amarin
Focused on improving the treatment of cardiovascular disease. The company’s cardiovascular programs capitalize on its expertise in the field of lipid science and the known therapeutic benefits of essential fatty acids in treating cardiovascular disease. (NASDAQ: AMRN)
Anthera Pharmaceuticals
Focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. (NASDAQ: ANTH)
Ascendis Pharma
Ascendis Pharma develops differentiated prodrug versions of high-value protein drugs, such as growth hormone. (NASDAQ:ASND)
Ascenta Therapeutics
Ascenta’s current focus is a portfolio of novel, orally-active, small molecule drugs that restore the natural potential for cancer cells to undergo cell death (apoptosis). All programs are patented.
aTyr Pharma
Focused on the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of Physiocrine biology, a newly discovered set of physiological modulators.
Audentes Therapeutics
Committed to the development and commercialization of innovative new treatments for people with serious, rare diseases through the application of gene therapy technology.
Auris Medical
Prevention or treatment of inner ear disorders, for acute inner ear tinnitus and for acute inner ear hearing loss. (NASDAQ:EARS)
Catalyst Biosciences
Creating novel catalytic biopharmaceutical products based on engineered human proteases.
Checkmate Pharmaceuticals
Developing novel approach to specifically activating the immune system to recognize and ultimately destroy tumor cells.
Chiasma
Late-stage biotech developing an oral drug candidate for acromegaly.
Coherus Biosciences
Coherus Biosciences one of our ealier companies is a biosimilar platform company that acquired Intekrin. (NASDAQ:CHRS)
First Aid Shot Therapy
Focused on the development and commercialization of a comprehensive portfolio of OTC pharmaceutical products in liquid \'shot\' format.
Histogenics
Combining cell therapy and tissue engineering technologies to develop highly innovative products for tissue repair and regeneration. (NASDAQ:HSGX)
Hyperion Therapeutics
Focused on the development of treatments that address critical unmet needs in the areas of gastroenterology and hepatology. (NADSAQ: HPTX)
Innocoll
Developing and manufacturing a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies. (NASDAQ: INNL)
Marinus Pharmaceuticals
Dedicated to the reformulation, development, and commercialization of novel drugs to treat serious neurological, psychiatric, and pain disorders including epilepsy. (NASDAQ: MRNS)
Mirna Therapeutics
Developing tumor suppressor microRNAs (miRNAs) to kill cancer cells by regaining control over multiple oncogenic pathways.
Natera
Natera is a privately-held, commercial stage genetic testing company that develops and commercializes non-invasive methods for analyzing DNA. The mission of the company is to help families diagnose and manage genetic disease.
NuCana
Developing and commercialising novel anti-cancer medicines including next generation nucleotide prodrugs.
ObsEva
Dedicated to the development of innovative drugs for women’s reproductive medicine including preterm labour.
Ocera
Focused on the development of drugs to treat a broad range of gastrointestinal and liver diseases. (NASDAQ: OCRX)
Ophthotech Corporation
Specializing in the development of novel therapeutics to treat diseases of the eye. (NASDAQ: OPHT)
Principia Biopharma
Focused on discovering and developing first-in-class small molecule drugs within the fields of autoimmune disease and oncology that are potent and safe.
Prothena
Advancing and developing novel antibodies for broad range of diseases involving protein misfolding or cell adhesion, including amyloidosis. (Nasdaq: PRTA)
Spark Therapeutics
Focused on developing curative, one-time gene therapy products their including lead gene therapy candidate, for RPE65-related blindness. (NASDAQ: ONCE)
Versartis
Developing therapeutics for the treatment of endocrine disorders, including human growth hormones. (NASDAQ: VSAR)
ZS Pharma
Focused on the treatment of kidney and liver diseases including hyperkalemia. (NASDAQ: ZSPH